Showing results (131-140 of 1,479) with videos related to
Sort By:
Pageof 148
Human Psychopharmacology|April 20, 2017
Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled studyFarzin Rezaei, Bita Mesgarpour, Alireza Jeddian, et al.Human Psychopharmacology|November 19, 2016
Attentional biases in patients with alcohol dependence: influence of coexisting psychopathologyJulia M A Sinclair, Matthew Garner, Sonja C Pasche, et al.Human Psychopharmacology|November 19, 2016
The effects of olanzapine treatment on brain regional glucose metabolism in neuroleptic-naive first-episode schizophrenic patientsHirofumi Yoshimuta, Masayuki Nakamura, Eisuke Kanda, et al.Human Psychopharmacology|November 19, 2016
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world studyPedro Damian Gargoloff, Ricardo Corral, Luis Herbst, et al.Human Psychopharmacology|February 8, 2008
Sustained attention and serotonin: a pharmaco-fMRI studyMarleen Wingen, Kim P C Kuypers, Vincent van de Ven, et al.Human Psychopharmacology|March 5, 2014
Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjectsTianmei Si, Yun'ai Su, Yi Liu, et al.Human Psychopharmacology|February 13, 2014
Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorderJun-Won Hwang, Bongseog Kim, Yeni Kim, et al.Human Psychopharmacology|March 8, 2014
Positive perception of pharmacogenetic testing for psychotropic medicationsMatthew B Lanktree, Gwyneth Zai, Laura E Vanderbeek, et al.Human Psychopharmacology|June 3, 2008
Ecstasy-related deficits in the updating component of executive processesCatharine Montgomery, John E FiskHuman Psychopharmacology|April 19, 2008
Executive function deficits in short-term abstinent cannabis usersSue McHale, Nigel HuntPageof 148